arrow
E

Emanuela Scarpi

irccs istituto romagnolo per lo studio dei tumori irst dino amadori
H指数:53
被引数:1.0万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Post-VABB Cavity-Targeted Avidin-Pretargeted [90Y]Y-DOTA-Biotin in Nonpalpable Breast Cancer: A Phase I Activity-Escalation Study (ARTHE)

术后VABB腔内靶向亲和素预靶向[90Y]Y-DOTA-生物素在非可触及乳腺癌中的应用:一项I期剂量递增研究(ARTHE)

Cancers
IF4.4
2026-08-280
OA
Identification of palliative care needs and prognostic factors of survival for tailoring appropriate interventions in advanced oncological, renal, and pulmonary diseases: results from a prospective observational study in an Italian population

识别姑息治疗需求及生存预后因素,以针对晚期肿瘤、肾脏和肺部疾病进行适当干预:来自意大利人群前瞻性观察研究的结果

2026-08-050
OAAI
Primary or specialist care at home: multicenter validation study of the “CP.BA.SPE 2025” questionnaire for the identification of the level of palliative care in advanced cancer patients

居家基础或专科护理:用于识别晚期癌症患者姑息护理水平的“CP.BA.SPE 2025”问卷的多中心验证研究

2026-03-310
OAAI
Survey on cancer patients’ attitudes towards AI and data protection: A cross-sectional study from an Italian cancer center

关于癌症患者对人工智能和数据保护态度的调查研究:一项来自意大利癌症中心的研究

2025-12-300
PRE
CombiCoR-Vax trial: study protocol for a phase II, single-arm, multicenter trial of sequential pembrolizumab plus dendritic cell vaccine followed by trifluridine/tipiracil and bevacizumab in refractory microsatellite-stable metastatic colorectal cancer

CombiCoR-Vax试验:一项关于序贯使用帕博利珠单抗联合树突状细胞疫苗,随后使用曲氟尿苷/ tipiracil 和贝伐珠单抗治疗难治性微卫星稳定型转移性结直肠癌的II期、单臂、多中心试验的研究方案

2025-11-230
OA
Investigating biochemical markers of Acupuncture's effectiveness in managing climacteric syndrome in breast cancer patients: the FLAIR study

探究针灸在管理乳腺癌患者围绝经期综合征有效性方面的生化标志物:FLAIR研究

2025-11-200
PRE
Exploring the promoter regions of cancer predisposition genes in patients with triple-negative breast cancer reveals the presence of rare germline variants

探索三阴性乳腺癌患者中癌症易感基因的启动子区域,发现存在罕见的胚系变异。

2025-05-080
OA
Adjuvant dendritic cell-based immunotherapy in melanoma: insights into immune cell dynamics and clinical evidence from a phase II trial

黑色素瘤的树突状细胞为基础的辅助免疫疗法:来自一项II期试验的免疫细胞动力学及临床证据

2025-04-180
OA
Dendritic cell vaccines as cancer treatment: focus on 13 years of manufacturing and quality control experience in advanced therapy medicinal products
2024-12-010
OAAI
Detection of circulating tumor DNA and chromosome 3p25.3 gain in relapsed/refractory germ cell tumors and impact of salvage high-dose chemotherapy: Results from the Italian Germ Cell Cancer Group 04 study

循环肿瘤DNA和3p25.3染色体增益在复发/难治性生殖细胞瘤中的检测及挽救性大剂量化疗的影响:意大利生殖细胞癌研究组04研究的结果

2024-09-010
PRE
Open-label, multicentre randomised trial of Radium223-docetaxel versus docetaxel-Radium223 sequence in metastatic castration resistant prostate cancer (mCRPC) with prospective biomarker evaluation (RAPSON study)

开放标签、多中心随机试验,比较镭223-多西他赛与多西他赛-镭223序贯疗法在转移性去势抵抗性前列腺癌(mCRPC)中的应用(并前瞻性评估生物标志物)(RAPSON研究)

2024-09-010
PRE
Correlation of [68Ga]Ga-PSMA PET/CT response and PSA decline in first-line enzalutamide for metastatic castration-resistant prostate cancer patients
2024-08-290
OAAI
Immunologic features and association with prognosis in hormone receptor positive/HER2-negative (HR+/HER2) metastatic breast cancer (MBC) treated with chemotherapy (CT) or CDK4/6-inhibitors (CDK4/6i) + endocrine therapy (ET)
2024-05-020
PRE
Inherited Mutations in DNA Damage Repair Genes in Italian Men with Metastatic Prostate Cancer: Results from the Meet-URO 10 Study
2024-03-014
OAAI
Advanced low grade serous ovarian cancer: A retrospective analysis of surgical and chemotherapeutic management in two high volume oncological centers

晚期低级别浆液性卵巢癌: 两个高容量肿瘤中心手术和化疗管理的回顾性分析

2022-09-2712
OAAI